SEC Form 4 · accession 0001232524-16-000386
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth W O'Keefe
Director
Period of report
Nov 11, 2016
Accepted (ET)
Nov 15, 2016 · 5:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Nov 11, 2016 | P | 1,200 | $114.3047 | A | 1,200 | I | by Trust |
| Ordinary SharesF1 | Nov 11, 2016 | P | 300 | $114.33 | A | 1,500 | I | by Trust |
| Ordinary SharesF2,F1 | Nov 14, 2016 | P | 500 | $112.447 | A | 2,000 | I | by Trust |
| Ordinary Shares | holding | — | — | — | 12,107 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares were acquired for the benefit of The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, of which the reporting person is both trustee and beneficiary.
- F2Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from $112.4000 to $112.4588. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were made.